PenderFund Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

PenderFund Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,180	Closed	-$502K	–	199
2022 Q2	$502K	Buy	+5,180	New	+$230K	0.14%	63

PenderFund Capital Management's TPTX Position: Q3 2022 in Review

PenderFund Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 5,180 shares — an estimated $502K sold.

PenderFund Capital Management first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $502K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

PenderFund Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
PenderFund Capital Management sold 5,180 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $502K.
PenderFund Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
PenderFund Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $502K in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on PenderFund Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.